Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Biosciences (INBX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is inhibrx-biosciences.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.